{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:12:02Z","timestamp":1695906722818},"reference-count":8,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2005,8,17]],"date-time":"2005-08-17T00:00:00Z","timestamp":1124236800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2005,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Sevelamer hydrochloride (SH) was registered as a new drug under the Japanese national health insurance scheme in 2003, and the Kidney Disease Outcomes Quality Initiative (K\/DOQI) guidelines for the treatment of renal osteodystrophy were released the same year. At that time, treatment objectives for hemodialysis outpatients at the Kojinkai Ishimaki Clinic were settled established and the outcomes reviewed 18\u2003months later. The relationship between the type and dosage of phosphate binder (PB), and the concentrations of adjusted calcium (Ca), phosphorus (P), intact parathyroid hormone (PTH), and bone alkaline phosphatase (BAP) was examined. Patients receiving calcitriol or maxacalcitol intravenous pulse therapy, or who had undergone simultaneous pancreas\u2013kidney transplant, were excluded from this analysis. The PB was CaCO<jats:sub>3<\/jats:sub> in 60% of cases, SH in 33.3%, and a combination of both in 21.9%; no PB was used in 6.7% of cases. The dosage of CaCO<jats:sub>3<\/jats:sub> was 2.8\u2003\u00b1\u20031.0\u2003g\/day, and 1\u03b1\u2010hydroxy activated vitamin D<jats:sub>3<\/jats:sub> (VD) was 0.46\u2003\u00b1\u20030.24\u2003\u00b5g\/day; the respective concentrations of adjusted Ca, P, intact PTH, and BAP were 9.4\u2003\u00b1\u20030.7\u2003mg\/dL, 5.6\u2003\u00b1\u20031.7\u2003mg\/dL, 104\u2003\u00b1\u200383.9\u2003pg\/mL, and 22.7\u2003\u00b1\u200310.9\u2003IU\/L. In the SH monotherapy group, the dosage of SH was 3.9\u2003\u00b1\u20030.725\u2003g\/day, and VD 0.62\u2003\u00b1\u20030.21\u2003\u00b5g\/day, and the concentrations for adjusted Ca, P, intact PTH, and BAP were 9.6\u2003\u00b1\u20030.4\u2003mg\/dL, 6.2\u2003\u00b1\u20031.5\u2003mg\/dL, 150\u2003\u00b1 42.9\u2003pg\/mL, and 38.5\u2003\u00b1\u200314.2\u2003IU\/L, respectively. In the combined therapy group, the dosage of CaCO<jats:sub>3<\/jats:sub> was 2.9\u2003\u00b1\u20030.9\u2003g\/day, SH was 3.3\u2003\u00b1\u20031.1\u2003g\/day, VD was 0.53\u2003\u00b1\u20030.27\u2003\u00b5g\/day, and the respective concentrations were 9.2\u2003\u00b1\u20031.0\u2003mg\/dL, 5.7\u2003\u00b1 1.4\u2003mg\/dL, 160\u2003\u00b1\u2003107.8\u2003pg\/mL, and 31.3\u2003\u00b1\u200342.0\u2003IU\/L. One\u2010third of all subjects were administered SH, either as monotherapy or in combination with CaCO<jats:sub>3<\/jats:sub>, and in these patients the dosage of VD was able to increase.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2005.00280.x","type":"journal-article","created":{"date-parts":[[2005,8,17]],"date-time":"2005-08-17T07:15:45Z","timestamp":1124262945000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Sevelamer Hydrochloride and the K\/DOQI Guidelines"],"prefix":"10.1111","volume":"9","author":[{"given":"Shigeru","family":"Yumita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.180.45"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-56-3-572"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90014-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607173150304"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111639"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000185272"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199307000-00006"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00905-3"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2005.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2005.00280.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T06:27:45Z","timestamp":1695796065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2005.00280.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":8,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1111\/j.1744-9987.2005.00280.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2005.00280.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}